Thrombotic microangiopathy adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,551 adverse event reports that record the MedDRA preferred term Thrombotic microangiopathy. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 867 reports in the 12 months to June 2026 and 764 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 683 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 867 (0.1%) record this term. Reports for patients aged 45 to 64 were 30.4% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 128 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Thrombotic microangiopathy name as a suspect product, in order of name
Drug	Class	Reports with this term
Abraxane	Microtubule inhibitor	38
Acyclovir	Herpes simplex virus nucleoside analog DNA polymerase inhibitor	39
Alemtuzumab	CD52-directed cytolytic antibody	99
Alkeran		41
Anti-thymocyte globulin (rabbit)	Immunoglobulin G	35
Antithymocyte Immunoglobulin		55
Atezolizumab	Programmed death Receptor-1 blocking antibody	34
Atorvastatin		28
Atovaquone	Antimalarial	71
Avastin	Vascular endothelial growth factor inhibitor	130
Azathioprine	Purine antimetabolite	125
Bactrim	Dihydrofolate reductase inhibitor antibacterial	51
Basiliximab	Interleukin-2 receptor blocking antibody	193
Belatacept	Selective T cell costimulation blocker	62
Bevacizumab	Vascular endothelial growth factor inhibitor	315
Bortezomib	Proteasome inhibitor	108
Budesonide	Corticosteroid	34
Busulfan	Alkylating drug	283
Busulfex		103
Capecitabine	Nucleoside metabolic inhibitor	56
Carboplatin	Platinum-based drug	312
Carfilzomib	Proteasome inhibitor	257
CellCept	Antimetabolite immunosuppressant	143
Certican		53
Ciclosporin		178
Ciprofloxacin	Fluoroquinolone antibacterial	26
Cisplatin	Platinum-based drug	121
Clopidogrel	P2Y12 platelet inhibitor	47
Cyclophosphamide	Alkylating drug	655
Cyclosporine	Calcineurin inhibitor immunosuppressant	739
Cytarabine	Nucleoside metabolic inhibitor	97
Daratumumab	CD38-directed cytolytic antibody	41
Darzalex	CD38-directed cytolytic antibody	31
Defitelio		47
Dexamethasone	Corticosteroid	320
Docetaxel	Microtubule inhibitor	75
Doxorubicin	Anthracycline topoisomerase inhibitor	90
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	48
Eculizumab	Complement inhibitor	103
Envarsus	Calcineurin inhibitor immunosuppressant	61
Etanercept	Tumor necrosis factor blocker	33
Etoposide	Topoisomerase inhibitor	294
Everolimus	Kinase inhibitor	184
Filgrastim	Leukocyte growth factor	46
Fludara		65
Fludarabine	Nucleoside metabolic inhibitor	386
Fludarabine phosphate	Nucleoside metabolic inhibitor	131
Fluorouracil	Nucleoside metabolic inhibitor	71
Furosemide	Loop diuretic	51
Ganciclovir	Cytomegalovirus nucleoside analog DNA polymerase inhibitor	91
Gemcitabine	Nucleoside metabolic inhibitor	678
Gemcitabine hydrochloride	Nucleoside metabolic inhibitor	252
Gemcitabine/Gemcitabine Hydrochloride		43
Gemzar		128
Human immunoglobulin g	Human immunoglobulin G	48
Hydrocortisone	Corticosteroid	57
Ibuprofen	Nonsteroidal anti-inflammatory drug	31
Ifosfamide	Alkylating drug	29
Imatinib	Kinase inhibitor	37
Isatuximab	CD38-directed cytolytic antibody	60
Keytruda	Programmed death Receptor-1 blocking antibody	33
Kyprolis	Proteasome inhibitor	149
Lacosamide		59
Lansoprazole	Proton pump inhibitor	58
Lapine t-lymphocyte immune globulin		56
Lenalidomide	Thalidomide analog	121
Levetiracetam		46
Levofloxacin	Fluoroquinolone antibacterial	45
Melphalan	Alkylating drug	330
Melphalan hydrochloride		29
Methotrexate	Folate analog metabolic inhibitor	446
Methotrexate sodium	Folate analog metabolic inhibitor	73
Methylprednisolone	Corticosteroid	368
Metronidazole	Nitroimidazole antimicrobial	25
Midazolam	Benzodiazepine	36
Mycophenolate		32
Mycophenolate mofetil	Antimetabolite immunosuppressant	946
Mycophenolate sodium		49
Mycophenolic acid	Antimetabolite immunosuppressant	134
Myfortic	Antimetabolite immunosuppressant	26
Neoral	Calcineurin inhibitor immunosuppressant	88
Opana Er		36
Oxaliplatin	Platinum-based drug	151
Oxazepam	Benzodiazepine	31
Paclitaxel	Microtubule inhibitor	163
Paxlovid		31
Pembrolizumab	Programmed death Receptor-1 blocking antibody	49
Phenobarbital		39
Phenytoin	Anti-epileptic agent	37
Pomalidomide	Thalidomide analog	55
Posaconazole	Azole antifungal	27
Prednisolone	Corticosteroid	382
Prednisone	Corticosteroid	356
Prograf	Calcineurin inhibitor immunosuppressant	423
Propofol	General anesthetic	40
Quetiapine	Atypical antipsychotic	34
Quinine	Antimalarial	54
Quinine sulfate	Antimalarial	37
Rapamune		77
Rebif	Interferon beta	55
Revlimid	Thalidomide analog	44
Rituximab	CD20-directed cytolytic antibody	278
Ruxolitinib	Janus kinase inhibitor	121
Sandimmune	Calcineurin inhibitor immunosuppressant	33
Simulect	Interleukin-2 receptor blocking antibody	47
Sirolimus	Kinase inhibitor	315
Soliris	Complement inhibitor	644
Solu-medrol	Corticosteroid	27
Sulfamethoxazole and trimethoprim	Dihydrofolate reductase inhibitor antibacterial	47
Sulfamethoxazole, trimethoprim	Dihydrofolate reductase inhibitor antibacterial	58
Sunitinib		29
Sutent	Kinase inhibitor	30
Tacrolimus	Calcineurin inhibitor immunosuppressant	2,185
Thiotepa	Alkylating drug	238
Thymocyte Immune Globulin		111
Thymoglobulin	Immunoglobulin G	142
Thymoglobuline		43
Trastuzumab	HER2/neu receptor antagonist	40
Treosulfan		50
Ultomiris	Complement inhibitor	30
Valganciclovir	Cytomegalovirus nucleoside analog DNA polymerase inhibitor	67
Valganciclovir hydrochloride	Cytomegalovirus nucleoside analog DNA polymerase inhibitor	37
Vancomycin	Glycopeptide antibacterial	49
Velcade	Proteasome inhibitor	59
Venetoclax	BCL-2 inhibitor	26
Vincristine		59
Vincristine sulfate	Vinca alkaloid	34
Zolgensma		50

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 55 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Thrombotic microangiopathy name, in order of name
Class	Reports with this term
Alkylating drug	1,592
Anthracycline topoisomerase inhibitor	148
Anti-epileptic agent	71
Antimalarial	180
Antimetabolite immunosuppressant	1,249
Antirheumatic agent	30
Atypical antipsychotic	49
Azole antifungal	95
BCL-2 inhibitor	28
Benzodiazepine	73
Biguanide	25
Calcineurin inhibitor immunosuppressant	3,533
CD20-directed cytolytic antibody	291
CD38-directed cytolytic antibody	140
CD52-directed cytolytic antibody	111
Cephalosporin antibacterial	46
Complement inhibitor	783
Corticosteroid	1,592
Cytomegalovirus nucleoside analog DNA polymerase inhibitor	197
Cytoprotective agent	45
Dihydrofolate reductase inhibitor antibacterial	170
Fluoroquinolone antibacterial	71
Folate analog metabolic inhibitor	544
General anesthetic	42
Glycopeptide antibacterial	56
HER2/neu receptor antagonist	65
Herpes simplex virus nucleoside analog DNA polymerase inhibitor	59
Human immunoglobulin G	72
Immunoglobulin G	180
Interferon beta	66
Interleukin-2 receptor blocking antibody	240
Janus kinase inhibitor	146
Kinase inhibitor	767
Leukocyte growth factor	52
Loop diuretic	62
Microtubule inhibitor	276
Nitroimidazole antimicrobial	36
Nonsteroidal anti-inflammatory drug	56
Nucleoside metabolic inhibitor	1,724
Opioid agonist	30
P2Y12 platelet inhibitor	78
Penicillin-class antibacterial	44
Platinum-based drug	584
Programmed death Receptor-1 blocking antibody	177
Proteasome inhibitor	596
Proton pump inhibitor	83
Purine antimetabolite	131
Pyrophosphate analog DNA polymerase inhibitor	33
Selective T cell costimulation blocker	62
Thalidomide analog	220
Topoisomerase inhibitor	313
Tumor necrosis factor blocker	73
Vascular endothelial growth factor inhibitor	463
Vascular endothelial growth factor receptor 2 antagonist	29
Vinca alkaloid	51

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Thrombotic microangiopathy, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Thrombotic microangiopathy
Age	Reports	Share
Under 2	242	2.5%
2 to 11	512	5.4%
12 to 17	312	3.3%
18 to 44	1,941	20.3%
45 to 64	2,906	30.4%
65 to 74	1,284	13.4%
75 and over	448	4.7%
Age not given	1,906	20%

Sex of the patient in the reports that record Thrombotic microangiopathy
Sex	Reports	Share
Female	4,231	44.3%
Male	3,859	40.4%
Unknown or not given	1,461	15.3%

Age and sex are as the report gives them. 31% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Thrombotic microangiopathy: adverse event reports that record this term. https://reportedreactions.com/reaction/thrombotic-microangiopathy/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Thrombotic microangiopathy mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page